Finch Therapeutics Group Inc is a biotechnology business based in the US. Finch Therapeutics Group shares (FNCH) are listed on the NASDAQ and all prices are listed in US Dollars. Finch Therapeutics Group employs 191 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Finch Therapeutics Group
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – FNCH – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Finch Therapeutics Group stock price (NASDAQ: FNCH)Use our graph to track the performance of FNCH stocks over time.
Finch Therapeutics Group shares at a glance
|Latest market close||$9.10|
|52-week range||$8.77 - $22.50|
|50-day moving average||$12.62|
|200-day moving average||$13.74|
|Wall St. target price||$30.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.78|
Buy Finch Therapeutics Group shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Finch Therapeutics Group stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Finch Therapeutics Group price performance over time
|1 week (2022-01-07)||-0.76%|
|1 month (2021-12-16)||-6.57%|
|3 months (2021-10-15)||-23.85%|
|6 months (2021-07-16)||-43.48%|
|1 year (2021-01-12)||N/A|
|2 years (2020-01-12)||N/A|
|3 years (2019-01-12)||N/A|
|5 years (2017-01-12)||N/A|
Finch Therapeutics Group financials
|Revenue TTM||$19.5 million|
|Gross profit TTM||$-25,425,000|
|Return on assets TTM||-18.33%|
|Return on equity TTM||-35.61%|
|Market capitalisation||$435.4 million|
TTM: trailing 12 months
Finch Therapeutics Group share dividends
We're not expecting Finch Therapeutics Group to pay a dividend over the next 12 months.
Finch Therapeutics Group overview
Finch Therapeutics Group, Inc. , a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that has completed Phase II clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and FIN-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and crohn's disease. The company has collaboration and license agreements with Millennium Pharmaceuticals, Inc. ; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc.
Finch Therapeutics Group in the news
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Two of Sen. Kyrsten Sinema's former aides have lobbied for corporate giants looking to influence Joe Biden's agenda
Joe Manchin's former aides gain influential lobbying clients as their ex-boss battles Biden's agenda
Frequently asked questionsWhat percentage of Finch Therapeutics Group is owned by insiders or institutions?
Currently 49.191% of Finch Therapeutics Group shares are held by insiders and 17.329% by institutions. How many people work for Finch Therapeutics Group?
Latest data suggests 191 work at Finch Therapeutics Group. When does the fiscal year end for Finch Therapeutics Group?
Finch Therapeutics Group's fiscal year ends in December. Where is Finch Therapeutics Group based?
Finch Therapeutics Group's address is: 200 Inner Belt Road, Somerville, MA, United States, 02143 What is Finch Therapeutics Group's ISIN number?
Finch Therapeutics Group's international securities identification number is: US31773D1019
More guides on Finder
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
Can Turo’s IPO do better than Uber and Airbnb?
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
NFT-funded LinksDAO moves $10.5 million closer to buying a golf course
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
How to buy Nexalin Technology (NXL) stock when it goes public
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
Ask an Expert